Hemochromatosis is diagnosed through a combination of blood tests that measure iron levels, followed by genetic testing to confirm whether the condition is hereditary. The process typically starts with two key blood markers: transferrin saturation and serum ferritin. A transferrin saturation of 45% or higher is the earliest and most reliable flag, and it often triggers further investigation even before symptoms appear.
Blood Tests That Signal Iron Overload
The two blood tests that form the foundation of diagnosis measure different things. Transferrin saturation tells you what percentage of your blood’s iron-carrying protein is loaded with iron. Serum ferritin reflects how much iron is stored in your liver. Both need to be evaluated together because each can be elevated for different reasons.
A transferrin saturation at or above 45% is generally considered too high and warrants further testing. For ferritin, the thresholds differ by sex: levels above 200 to 300 micrograms per liter are considered elevated in men, while levels above 150 to 200 micrograms per liter are elevated in women. These ranges vary slightly between labs, so your results will typically include the specific reference range used.
One practical detail worth knowing: there’s no strong evidence that you need to fast before these tests. Studies comparing fasting and non-fasting samples found no meaningful difference in accuracy for detecting hemochromatosis. A repeat value after fasting is just as likely to go up as down. If your doctor orders the test without requiring you to fast, that’s supported by the evidence.
Ferritin can be elevated by inflammation, infection, liver disease, and heavy alcohol use, so a high ferritin alone doesn’t confirm hemochromatosis. Transferrin saturation is a more specific indicator of true iron overload, which is why it’s often the first test to prompt genetic testing.
Genetic Testing Confirms the Type
Once blood tests suggest iron overload, the next step is genetic testing for mutations in the HFE gene. Three variants are routinely tested: C282Y, H63D, and S65C. The results determine not just whether you have hereditary hemochromatosis but also how likely you are to develop serious complications.
Having two copies of the C282Y mutation (one from each parent) carries the highest risk for iron overload. This pattern, called C282Y homozygosity, accounts for 80% to 85% of typical hereditary hemochromatosis cases. It’s most common in people of northern European descent, particularly those with Nordic or Celtic ancestry, where the condition affects roughly 1 in 220 to 250 people.
Compound heterozygosity, meaning one copy of C282Y paired with one copy of H63D or S65C, carries a moderate genetic risk but a very low chance of actual symptoms. Fewer than 2% of people with these combinations develop clinical problems. Having just one copy of any single variant, or two copies of H63D alone, rarely causes iron overload unless another undetected mutation is also present.
An important nuance: even among people with two copies of C282Y, only a minority develop clinical symptoms. The genetic test confirms your risk category, but it doesn’t tell the whole story. Your iron levels, symptoms, and organ function matter just as much for deciding on treatment.
When HFE Testing Comes Back Negative
If your iron levels are clearly elevated but HFE testing is negative or inconclusive, rarer forms of hemochromatosis may be the cause. Mutations in genes called HJV, HAMP, and TFR2 all regulate iron metabolism and can cause iron overload that looks clinically similar to classic hemochromatosis but tends to show up earlier and progress faster.
Mutations in HJV or HAMP cause what’s sometimes called juvenile hemochromatosis, with a mean age of diagnosis in the mid-20s. These forms tend to be the most severe. TFR2 mutations cause an intermediate severity, typically diagnosed in the early 30s, compared to the early 40s for classic HFE disease. Where available, next-generation sequencing panels can test for these rarer mutations, which also allows for targeted screening of your family members.
Assessing Liver Damage
Once hemochromatosis is confirmed, doctors need to know whether iron has already damaged your liver. This determines your prognosis and how aggressively treatment needs to proceed.
MRI is now the primary tool for measuring liver iron without a needle. The technique works because iron in liver tissue changes how the organ responds to the magnetic field, producing a measurable signal drop that correlates with the amount of stored iron. Normal liver iron concentration is below 36 micromoles of iron per gram of tissue. Significant iron overload starts at 60, and levels at or above 80 fall squarely in the hemochromatosis range.
Liver biopsy was once the standard for diagnosis, but advances in MRI and genetic testing have made it unnecessary in many cases. It still plays a role in specific situations: when imaging results are ambiguous, when the genetic profile doesn’t match a common pattern, or when there isn’t enough clinical evidence to confirm the diagnosis confidently. Its most important remaining function is staging fibrosis, the degree of scarring in the liver, which directly affects prognosis and the risk of liver cancer. A formula combining your age and liver iron concentration can predict severe fibrosis with high accuracy, which sometimes helps doctors decide whether a biopsy is needed.
Symptoms That Lead to Testing
Many people with hemochromatosis have no symptoms at all for years, and when symptoms do appear, they’re easy to attribute to other causes. The most common early complaints are fatigue, weakness, and joint pain, particularly in the knees and hands. Abdominal pain over the liver area, loss of sex drive, erectile dysfunction in men, and missed periods in women are also common early signs.
Symptoms typically begin after age 40, and women tend to develop them about 10 years later than men because menstruation provides a natural route for iron loss during reproductive years. A distinctive skin change, a gray, metallic, or bronze discoloration, is one of the more recognizable signs. When combined with diabetes, this pattern is sometimes called “bronze diabetes.”
More advanced iron overload can cause cirrhosis, diabetes, heart rhythm disturbances, heart failure, and vision changes. Because the early symptoms overlap with dozens of common conditions, hemochromatosis is often caught incidentally through routine blood work or family screening rather than through symptom-driven testing.
Screening Family Members
Whenever someone is diagnosed with hemochromatosis, screening of first-degree relatives (parents, siblings, and children) is recommended. Since the condition is inherited in an autosomal recessive pattern, siblings of a diagnosed person have the highest probability of also carrying two copies of the mutation.
For children of someone with hemochromatosis, testing can generally be deferred until late adolescence. The condition has low clinical penetrance, meaning symptoms develop slowly and rarely cause problems before adulthood. Screening involves the same combination of iron studies and HFE genetic testing used for the initial diagnosis, and catching it early in a family member allows for monitoring and treatment long before organ damage begins.